Dynatronics Corporation designs, manufactures, and sells orthopedics, physical therapy, rehabilitation, pain management, and athletic training products in the United States and internationally.
Flawless balance sheet and fair value.
Share Price & News
How has Dynatronics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DYXA's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: DYXA underperformed the German Medical Equipment industry which returned 6.5% over the past year.
Return vs Market: DYXA underperformed the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Dynatronics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Dynatronics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DYXA (€0.73) is trading below our estimate of fair value (€20.79)
Significantly Below Fair Value: DYXA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DYXA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: DYXA is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DYXA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DYXA is good value based on its PB Ratio (0.7x) compared to the DE Medical Equipment industry average (5x).
How is Dynatronics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DYXA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DYXA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DYXA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DYXA's revenue is expected to decline over the next 3 years (-0.6% per year).
High Growth Revenue: DYXA's revenue is forecast to decline over the next 3 years (-0.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DYXA's Return on Equity is forecast to be high in 3 years time
How has Dynatronics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DYXA is currently unprofitable.
Growing Profit Margin: DYXA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DYXA is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare DYXA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DYXA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.9%).
Return on Equity
High ROE: DYXA has a negative Return on Equity (-4%), as it is currently unprofitable.
How is Dynatronics's financial position?
Financial Position Analysis
Short Term Liabilities: DYXA's short term assets ($19.6M) exceed its short term liabilities ($14.4M).
Long Term Liabilities: DYXA's short term assets ($19.6M) exceed its long term liabilities ($6.7M).
Debt to Equity History and Analysis
Debt Level: DYXA's debt to equity ratio (24.1%) is considered satisfactory.
Reducing Debt: DYXA's debt to equity ratio has reduced from 39.8% to 24.1% over the past 5 years.
Inventory Level: DYXA has a high level of physical assets or inventory.
Debt Coverage by Assets: DYXA's debt is covered by short term assets (assets are 3.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable DYXA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: DYXA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 28.5% per year.
What is Dynatronics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DYXA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate DYXA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DYXA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DYXA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DYXA's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brian Baker (52yo)
Mr. Brian D. Baker is the Chief Executive Officer, President and Director of Dynatronics Corporation since August 26, 2019 and has served as its Chief Operating Officer since May 29, 2019 until August 26, ...
CEO Compensation Analysis
Compensation vs Market: Brian's total compensation ($USD167.90K) is below average for companies of similar size in the German market ($USD428.66K).
Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||0.083yr||no data||no data|
|General Counsel||0.33yr||no data||no data|
|Corporate Controller||2.25yrs||no data||no data|
|Consultant||no data||no data||no data|
Experienced Management: DYXA's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
|Independent Director||4.33yrs||US$48.60k||0.71% $55.2k|
|Independent Director||4.33yrs||US$48.60k||0.71% $55.2k|
|Independent Chairman of the Board||2.17yrs||US$48.60k||13.5% $1.1m|
|Independent Director||6.83yrs||US$38.60k||0.59% $45.8k|
|Independent Director||4.75yrs||US$38.60k||1.48% $114.9k|
Experienced Board: DYXA's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.
Dynatronics Corporation's company bio, employee growth, exchange listings and data sources
- Name: Dynatronics Corporation
- Ticker: DYXA
- Exchange: BST
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$8.398m
- Listing Market Cap: US$7.784m
- Shares outstanding: 9.95m
- Website: https://www.dynatronics.com
Number of Employees
- Dynatronics Corporation
- 7030 Park Centre Drive
- Cottonwood Heights
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|DYNT||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Nov 1983|
|DYXA||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||Nov 1983|
Dynatronics Corporation designs, manufactures, and sells orthopedics, physical therapy, rehabilitation, pain management, and athletic training products in the United States and internationally. The company offers orthopedic soft bracing and support products, which include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also provides power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, treadmills, recumbent bikes, and other equipment. In addition, the company offers therapeutic modality devices, such as electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold therapy, compression therapy, and electrodes. Further, it provides clinical supplies, including exercise bands and tubing, topical analgesics, lotions and gels, orthopedic bracing, paper products, athletic tape, and other products. Dynatronics Corporation distributes its products under the Bird & Cronin, Dynatron Solaris, Hausmann, and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, and athletic trainers, sports medicine practitioners, hospitals, clinics, and consumers. It also exports its products to approximately 30 countries. The company was founded in 1979 and is headquartered in Cottonwood Heights, Utah.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/06 03:31|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.